Literature DB >> 1277713

Disposition kinetics of two oral forms of quinidine.

W A Mahon, M Mayersohn, T Inaba.   

Abstract

There are relatively few studies on the disposition properties of quinidine. We have studied in 10 normal subjects conventional quinidine sulfate and a slow-release quinidine bisulfate. Single and repetitive doses were given; blood and urine concentrations were measured by the method of Cramer and Isaakson. After a single dose of two tablets of quinidine sulfate (400 mg), the average peak concentration was 2.13 +/-0.22 mug/ml (+/-SEM); following two tablets of the slow-release form, the average peak concentration was 1.17 +/-0.12 mug/ml. T-max was approximately 2 hr with quinidine sulfate and 4 hr with quinidine bisulfate. One fourth of both forms of the drug was recovered in the urine. Total body clearance was 0.36 L/kg-hr and renal clearance was 117 +/-22ml/min for both. With multiple dosing the serum quinidine concentration was higher than these predicted from the results of the single-dose study. Based on the mean estimates of quinidine half-life of 6 hr, a rapid method for achieving steady-state levels of quinidine would be to give an initial dose twice that of the maintenance dose. With the slow-release product if an equivalent dose was given every 12 hr, the mean steady-state quinidine serum concentration would be approximately the same.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1277713     DOI: 10.1002/cpt1976195part1566

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine.

Authors:  M Davidian; A R Gallant
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

3.  Dose-dependence of the pharmacokinetics of quinidine.

Authors:  P Bolme; U Otto
Journal:  Eur J Clin Pharmacol       Date:  1977-08-17       Impact factor: 2.953

4.  A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.

Authors:  M D Nielsen; K Brøsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

5.  Divergence in pharmacokinetic parameters of quinidine obtained by specific and nonspecific assay methods.

Authors:  T W Guentert; R A Upton; N H Holford; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1979-06

6.  Absolute bioavailability of quinidine in two sustained release preparations.

Authors:  J P Amlie; L Storstein; B Olsson; D Fremstad; S Jacobsen
Journal:  Eur J Clin Pharmacol       Date:  1979-08       Impact factor: 2.953

7.  Absorption of quinidine from an enteric-coated preparation.

Authors:  D Fremstad; O G Nilsen; J Amlie; L Storstein; B Olsson; S Jacobsen
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

8.  Comparative bioavailability study of three sustained release quinidine formulations.

Authors:  W A Mahon; J S Leeder; M M Brill-Edwards; J Correia; S M MacLeod
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

10.  Quinidine dosage, with special reference to an oral loading dose schedule.

Authors:  P Collste; R Nordlander
Journal:  Br J Clin Pharmacol       Date:  1979-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.